Skip to main content
. 2008 Mar 28;283(13):8469–8476. doi: 10.1074/jbc.M708502200

FIGURE 4.

FIGURE 4.

Neutralization of EGFR. HeLa cells were pretreated for 2 h with 1 μg/ml mAb 528, a mouse monoclonal antibody that prevents EGF from binding to EGFR (even-numbered lanes) followed by treatment for 30 min with vehicle (lanes 1 and 2) or 1.5 nm commercial IFNα A(lanes 3 and 4), IFNα·EGF chimeric activator proteins containing wild-type or mutant IFNα-2a (CA-WT, lanes 5 and 6; CA-K133A, lanes 9 and 10; CA-R144A, lanes 13 and 14; or CA-R149A, lanes 17 and 18), or the corresponding wild-type or mutant IFNα-2a proteins (lanes 7 and 8, 11 and 12, 15 and 16, and 19 and 20). rhIFNα stands for recombinant human interferon α.